The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...
Recent research has focused on innovative treatments that target the underlying causes of CF, particularly through the development of CFTR (cystic fibrosis transmembrane conductance regulator ...
Sionna Therapeutics, Inc SION IPO will take place February, 07 on the NASDAQ exchange under the ticker SION. The company is ...
Irish Independent on MSN11d
Wicklow mother calls for access to life-saving therapy for son with rare form of Cystic FibrosisA Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...
Cystic fibrosis is a life-shortening disease with a worldwide prevalence. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene result in a reduction or absence of CFTR ...
New Delhi: Pharmaceutical major Dr Reddy's has got approval from the Subject Expert Committee (SEC) functional under the ...
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
In people with CF, mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene cause the CFTR protein to become dysfunctional. When the protein is not working correctly, it’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback